Biomind Labs Inc. (BMNDF) Stock

About Biomind Labs Inc.

Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Among its leading pipeline assets, BMND01 is currently in Phase II clinical trials for treating depression. Another key candidate, BMND08, a derivative of 5-Methoxy-N,N-dimethyltryptamine, is also in Phase II trials, addressing depression and anxiety specifically in patients experiencing cognitive decline associated with Alzheimer's disease. The company's broader development portfolio includes early-stage and preclinical candidates such as BMND02 for fibromyalgia, BMND03 for substance use disorders, BMND05 for persistent pain management, BMND06 for inflammatory conditions, and BMND07 for severe clinical depression. Biomind Labs Inc. maintains its headquarters in Canelones, Uruguay.

Biomind Labs Inc. is headquartered in CA.

Biomind Labs Inc. (BMNDF) stock trades at $0.15 with a market capitalization of $11.35M. The stock is valued at a price-to-earnings (P/E) ratio of -12.72, price-to-book of -6.26, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $0.15, and currently trades at its 52-week high.

On profitability, Biomind Labs Inc. generates a return on equity (ROE) of 54.12% — well above the market average, a sign of a high-quality business, return on capital employed of 45.11%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.biomindlabs.com